Interventional cardiologists now have multiple effective, evidence-backed strategies to treat calcified coronary lesions, with new data showing both intravascular lithotripsy (IVL) and super-high-pressure balloons are leading options, though a clear winner has not yet emerged, according to experts at TCT 2026.
TCTMD reports that while both modalities remain leading management strategies, the choice may vary based on personal preference and institutional availability.
““Calcium is the last frontier of PCI, and in 2026, the evidence is finally catching up with the technology,”” said Armando Pérez de Prado, MD, PhD (University Hospital of León, Spain), session moderator at TCT 2026. TCTMD reports he noted that while there is no “clear winner,” real-life evidence must be balanced with trial data.
New NCDR CathPCI Registry data presented at TCT 2026 showed a significant increase in Shockwave IVL use, growing from under 30,000 cases in 2022 to over 250,000 in 2025. TCTMD reports that in a study of 254,674 patients, the site-reported procedural success rate was 95.7%, with rates of perforation, dissection, and MI all below 1%.

Another study, the TECTONIC CAD IVL IDE trial, found the investigational SonicForce IVL system (Abbott) achieved a primary safety endpoint of target lesion failure at 30 days of just 0.3% and a primary efficacy endpoint of procedural success of 97.0%. TCTMD reports that the findings, published in JACC: Cardiovascular Interventions, showed no instances of cardiac death and a MACE rate of 0.3% at 30 days.
The VICTORY trial, presented at TCT 2025, compared the super-high-pressure OPN NCB balloon with IVL for treating heavily calcified coronary lesions. PCRonline reports that the trial enrolled 278 patients to assess whether lesion preparation with OPN NCB is non-inferior to IVL in terms of final stent expansion measured by OCT.
The study found severe calcification was detected angiographically in 40% of patients and by OCT in 43-45%. The procedure time was numerically higher in the IVL arm (mean 79 vs 70 minutes; P = 0.06), and the use of NCB prior to the study device was significantly higher in the IVL arm (40% vs 23%).